1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
2
|
Fornari F, Ferracin M, Trerè D, Milazzo M,
Marinelli S, Galassi M, Venerandi L, Pollutri D, Patrizi C, Borghi
A, et al: Circulating microRNAs, miR-939, miR-595, miR-519d and
miR-494, identify cirrhotic patients with HCC. PLoS One.
10:e01414482015. View Article : Google Scholar : PubMed/NCBI
|
3
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kassahun WT, Fangmann J, Harms J, Hauss J
and Bartels M: Liver resection and transplantation in the
management of hepatocellular carcinoma: A review. Exp Clin
Transplant. 4:549–558. 2006.PubMed/NCBI
|
5
|
Dilou N, Patouillard B and Audigier JC:
Staging systems in hepatocellular carcinoma. Gastroenterol Clin
Biol. 28:359–366. 2004.(In French). View Article : Google Scholar : PubMed/NCBI
|
6
|
Ono K, Kuwabara Y and Han J: MicroRNAs and
cardiovascular diseases. FEBS J. 278:1619–1633. 2011. View Article : Google Scholar : PubMed/NCBI
|
7
|
Lim LP, Lau NC, Garrett-Engele P, Grimson
A, Schelter JM, Castle J, Bartel DP, Linsley PS and Johnson JM:
Microarray analysis shows that some microRNAs downregulate large
numbers of target mRNAs. Nature. 433:769–773. 2005. View Article : Google Scholar : PubMed/NCBI
|
8
|
Zhao S, Li J, Zhang G, Wang Q, Wu C, Zhang
Q, Wang H, Sun P, Xiang R and Yang S: Exosomal miR-451a functions
as a tumor suppressor in hepatocellular carcinoma by targeting
LPIN1. Cell Physiol Biochem. 53:19–35. 2019. View Article : Google Scholar : PubMed/NCBI
|
9
|
Wu J, Huang WJ, Xi HL, Liu LY, Wang ST,
Fan WZ and Peng BG: Tumor-suppressive miR-3650 inhibits tumor
metastasis by directly targeting NFASC in hepatocellular carcinoma.
Aging (Albany NY). 11:3432–3434. 2019. View Article : Google Scholar : PubMed/NCBI
|
10
|
Chen S, Wang L, Yao B, Liu Q and Guo C:
miR-1307-3p promotes tumor growth and metastasis of hepatocellular
carcinoma by repressing DAB2 interacting protein. Biomed
Pharmacother. 117:1090552019. View Article : Google Scholar : PubMed/NCBI
|
11
|
Zhang J, Zhu Y, Hu L, Yan F and Chen J:
miR-494 induces EndMT and promotes the development of HCC
(hepatocellular carcinoma) by targeting SIRT3/TGF-β/SMAD signaling
pathway. Sci Rep. 9:72132019. View Article : Google Scholar : PubMed/NCBI
|
12
|
Tang J, Zhuo H, Zhang X, Jiang R, Ji J,
Deng L, Qian X, Zhang F and Sun B: A novel biomarker Linc00974
interacting with KRT19 promotes proliferation and metastasis in
hepatocellular carcinoma. Cell Death Dis. 5:e15492014. View Article : Google Scholar : PubMed/NCBI
|
13
|
Gurrapu S, Pupo E, Franzolin G, Lanzetti L
and Tamagnone L: Sema4C/PlexinB2 signaling controls breast cancer
cell growth, hormonal dependence and tumorigenic potential. Cell
Death Differ. 25:1259–1275. 2018. View Article : Google Scholar : PubMed/NCBI
|
14
|
Wei JC, Yang J, Liu D, Wu MF, Qiao L, Wang
JN, Ma QF, Zeng Z, Ye SM, Guo ES, et al: Tumor-associated lymphatic
endothelial cells promote lymphatic metastasis by highly expressing
and secreting SEMA4C. Clin Cancer Res. 23:214–224. 2017. View Article : Google Scholar : PubMed/NCBI
|
15
|
Le AP, Huang Y, Pingle SC, Kesari S, Wang
H, Yong RL, Zou H and Friedel RH: Plexin-B2 promotes invasive
growth of malignant glioma. Oncotarget. 6:7293–7304. 2015.
View Article : Google Scholar : PubMed/NCBI
|
16
|
Lu J, Lin Y, Li F, Ye H, Zhou R, Jin Y, Li
B, Xiong X and Cheng N: miR-205 suppresses tumor growth, invasion,
and epithelial-mesenchymal transition by targeting SEMA4C in
hepatocellular carcinoma. FASEB J. 32:fj201800113R2018. View Article : Google Scholar
|
17
|
Wu H, Wang X, Liu S, Wu Y, Zhao T, Chen X,
Zhu L, Wu Y, Ding X, Peng X, et al: Sema4C participates in myogenic
differentiation in vivo and in vitro through the p38 MAPK pathway.
Eur J Cell Biol. 86:331–344. 2007. View Article : Google Scholar : PubMed/NCBI
|
18
|
Wang ZF, Liao F, Wu H and Dai J: Glioma
stem cell-derived exosomal miR-26a promotes angiogenesis of
microvessel endothelial cells in glioma. J Exp Clin Cancer Res.
38:2012019. View Article : Google Scholar : PubMed/NCBI
|
19
|
Zhang J, Hou L, Liang R, Chen X, Zhang R,
Chen W and Zhu J: CircDLST promotes the tumorigenesis and
metastasis of gastric cancer by sponging miR-502-5p and activating
the NRAS/MEK1/ERK1/2 signaling. Mol Cancer. 18:802019. View Article : Google Scholar : PubMed/NCBI
|
20
|
Ma M, Dai J, Tang H, Xu T, Yu S, Si L, Cui
C, Sheng X, Chi Z, Mao L, et al: MicroRNA-23a-3p inhibits mucosal
melanoma growth and progression through targeting adenylate cyclase
1 and attenuating cAMP and MAPK pathways. Theranostics. 9:945–960.
2019. View Article : Google Scholar : PubMed/NCBI
|
21
|
Thorns C, Schurmann C, Gebauer N,
Wallaschofski H, Kümpers C, Bernard V, Feller AC, Keck T, Habermann
JK, Begum N, et al: Global microRNA profiling of pancreatic
neuroendocrine neoplasias. Anticancer Res. 34:2249–2254.
2014.PubMed/NCBI
|
22
|
Nordentoft I, Birkenkamp-Demtroder K,
Agerbæk M, Theodorescu D, Ostenfeld MS, Hartmann A, Borre M,
Ørntoft TF and Dyrskjøt L: miRNAs associated with chemo-sensitivity
in cell lines and in advanced bladder cancer. BMC Med Genomics.
5:402012. View Article : Google Scholar : PubMed/NCBI
|
23
|
Epis MR, Giles KM, Kalinowski FC, Barker
A, Cohen RJ and Leedman PJ: Regulation of expression of
deoxyhypusine hydroxylase (DOHH), the enzyme that catalyzes the
activation of eIF5A, by miR-331-3p and miR-642-5p in prostate
cancer cells. J Biol Chem. 287:35251–35259. 2012. View Article : Google Scholar : PubMed/NCBI
|
24
|
Ye SM, Han M, Kan CY, Yang LL, Yang J, Ma
QF and Wang SX: Expression and clinical significance of Sema4C in
esophageal cancer, gastric cancer and rectal cancer. Zhonghua Yi
Xue Za Zhi. 92:1954–1958. 2012.(In Chinese). PubMed/NCBI
|
25
|
Song J and Li Y: miR-25-3p reverses
epithelial-mesenchymal transition via targeting Sema4C in
cisplatin-resistance cervical cancer cells. Cancer Sci. 108:23–31.
2017. View Article : Google Scholar : PubMed/NCBI
|
26
|
Zhang Y and Huang S: Up-regulation of
miR-125b reverses epithelial-mesenchymal transition in
paclitaxel-resistant lung cancer cells. Biol Chem. Aug
20–2015.(Epub ahead of print). doi: 10.1515/hsz-2015-0153.
View Article : Google Scholar
|
27
|
Li J, Wang Q, Wen R, Liang J, Zhong X,
Yang W, Su D and Tang J: miR-138 inhibits cell proliferation and
reverses epithelial-mesenchymal transition in non-small cell lung
cancer cells by targeting GIT1 and SEMA4C. J Cell Mol Med.
19:2793–2805. 2015. View Article : Google Scholar : PubMed/NCBI
|
28
|
Chen J, Ji T, Wu D, Jiang S, Zhao J, Lin H
and Cai X: Human mesenchymal stem cells promote tumor growth via
MAPK pathway and metastasis by epithelial mesenchymal transition
and integrin α5 in hepatocellular carcinoma. Cell Death Dis.
10:4252019. View Article : Google Scholar : PubMed/NCBI
|
29
|
Chatterjee S, Patra D, Chakraborti U,
Sengupta D, Ghosh P, Basu A, Sadhukhan GC and Chowdhury KD:
Association of p38 MAPK-p53-Fas aggregation in S-allyl cysteine
mediated regulation of hepatocarcinoma. Environ Toxicol.
34:928–940. 2019. View Article : Google Scholar : PubMed/NCBI
|
30
|
Zhang GP, Yue X and Li SQ: Cathepsin C
interacts with TNF-alpha/p38 MAPK signaling pathway to promote
proliferation and metastasis in hepatocellular carcinoma. Cancer
Res Treat. 52:10–23. 2020. View Article : Google Scholar : PubMed/NCBI
|